Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Immunovant (Nasdaq: IMVT) will report financial results for the third quarter ended December 31, 2025 and provide a business update on Friday, February 6, 2026 at 8:00 a.m. ET.

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) will report financial results for the third quarter ended December 31, 2025 and provide a business update on Friday, February 6, 2026 at 8:00 a.m. ET. Investors can access a conference call (phone registration required) hosted with Roivant (Nasdaq: ROIV) and a live webcast. Presentation materials and a webcast archive will be available in the Investors "News & Events" section of Immunovant's website after the call.

Argus Jan 26 session

+2.27% close to close Open Argus

Details

News Market Reaction – IMVT

In the Jan 26 session, IMVT gained 2.27%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Immunovant’s third‑quarter results for the period ended Dec...

Analysis

This announcement sets the timetable for Immunovant’s third‑quarter results for the period ended December 31, 2025, with a business update scheduled for 8:00 a.m. ET on February 6, 2026. Recent history shows that detailed clinical readouts and financing terms have driven the largest moves, while prior earnings and scheduling updates produced smaller, mixed reactions. Investors reviewing this event may focus on how upcoming commentary relates to cash runway, ongoing registrational trials, and previously highlighted Graves’ disease milestones.

Key Figures

Earnings call time: 8:00 a.m. ET Quarter end date: December 31, 2025

Earnings call time

8:00 a.m. ET

Scheduled business update on February 6, 2026

Quarter end date

December 31, 2025

Third quarter reporting period referenced in announcement

Historical Context

5 past events · Latest: Dec 11

5 events

1. Dec 11

   Equity financing

   24h Move

   +5.3%

   Priced $550M common stock offering at $21.00 per share.

2. Nov 10

   Earnings and updates

   24h Move

   +0.1%

   Reported Q2 financials and multi-indication IMVT-1402 clinical updates.

3. Oct 27

   Earnings date notice

   24h Move

   +2.6%

   Announced timing and access details for upcoming Q2 results call.

4. Sep 03

   Clinical data update

   24h Move

   +10.8%

   Reported six‑month remission and treatment-free data in Graves’ disease.

5. Aug 11

   Earnings and pipeline

   24h Move

   -4.5%

   Quarterly results with higher R&D and progress on registrational studies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com

Media
Stephanie Lee
stephanie.lee@roivant.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Immunovant (IMVT) report Q3 2026 financial results?

Immunovant will report results for the third quarter ended December 31, 2025 on February 6, 2026 at 8:00 a.m. ET.

How can investors join the Immunovant (IMVT) earnings call on February 6, 2026?

Investors may register online to access the conference call by phone and can join the live webcast via the company's Investors "News & Events" page.

Will Immunovant (IMVT) provide slides or a webcast of the February 6, 2026 update?

Yes. Presentation materials and a webcast will be available during the event and an archived webcast will be posted on Immunovant's investor website after the call.

Is Roivant (ROIV) involved in the Immunovant (IMVT) February 6, 2026 call?

The notice indicates access to the Roivant (Nasdaq: ROIV) conference call by phone is available via online registration.

Where can I find the archived webcast and presentation for Immunovant (IMVT)?

The archived webcast and presentation will be posted under Investors > News & Events on Immunovant's website after the conference call.